You are here : Home > Projet NANOATHERO

Europe | Health & life sciences


NANOATHERO

With more than 6 million new cases of Cardio-Vascular Disease (CVD) in the EU every year, the disease remains the leading cause of mortality and the major cause of morbidity in Europe. Nano-Athero aims to establish the preliminary clinical feasibility of implementing nanosystems for targeted imaging and treatment of advanced atherothrombotic disease in humans.



Published on 4 May 2021



Nanomedicine for target-specific imaging and treatment of atherothrombosis


With more than 6 million new cases of Cardio-Vascular Disease (CVD) in the EU every year, the disease remains the leading cause of mortality and the major cause of morbidity in Europe. Nano-Athero aims to establish the preliminary clinical feasibility of implementing nanosystems for targeted imaging and treatment of advanced atherothrombotic disease in humans.



 

Starting date : Feb. 2013 > Jul. 2018

Lifetime: 66 months


Program in support :  FP7 NMP.2012.1.2-2 

Development and phase-I clinical trials of novel therapeutic nanotechnologyenabled systems for the diagnosis and treatment of atherosclerosis


 

Status project : complete


CEA-Leti's contact :

Isabelle Texier-Nogues


 

Project Coordinator: INSERM (FR)

Partners:  

  • AT: Medical University of Graz
  • CH: CLINAM - European Foundation for Clinical Nanomedicine
  • DE: Max Planck Institute of Colloids and Interfaces, nanoPET Pharma GmbH, Universitätsklinikum Erlangen
  • DK: Lundbeckfonden Center of Excellence in Nanomedicine NanoCAN
  • FR: CEA-Leti, CEA-DSV, Hopitaux de Paris, Inserm, Inserm-Transfert SA
  • GB: Edinethics Ltd
  • HU: Semmelweis University
  • IL: WinzSoft
  • IT: Bracco Imaging S.p.A
  • NL: Academic Medical Center, University of Twente

Target market: n/a



Publications:

  • «From Design to the Clinic: Practical Guidelines for
    Translating Cardiovascular Nanomedicine», I. Cicha,
    C. Chauvierre, I. Texier, C. Cabella, J.- M. Metselaar,
    J. Szebeni, C. Alexiou, F. Rouzet, G. Storm, E. Stroes, D. Bruce,
    N. MacRitchie, P. Maffia, D. Letourneur, Cardiovasc Res.
    114(13), 1714-1727, doi: 10.1093/cvr/cvy219 (2018).
  • «Comparative analysis of nanosystems’effects on human
    endothelial and monocytic cell functions», J. Matuszak,
    P. Dörffler, S. Lyer, H. Unterweger, M. Juenet, C. Chauvierre,
    A. Allarg, D. Franke, G. Almer, I. Texier, J.-M. Metselaar,
    R. Prassl, C. Alexiou, H. Mangge, D. Letourneur, I. Cicha,
    Nanotoxicology 28:1-18, doi:
    10.1080/17435390.2018.1502375 (2018).
  • «Nanoparticles for intravascular applications:
    Physicochemical characterization and cytotoxicity testing»,
    J. Matuszak, J. Baumgartner, J. Zaloga, M. Juenet,
    A. Eduardo da Silva, D. Franke, G. Almer, I. Texier, D. Faivre,
    J.-M. Metselaar, F.-P. Navarro, C. Chauvierre, R. Prassl,
    L. Dézsi, R. Urbanics, C. Alexiou, H. Mangge, J. Szebeni,
    D. Letourneur, I. Cicha, (NanoAthero Consortium),
    Nanomedicine, Vol. 11, No. 6, Pages 597-616, March 2016.
  • «Nanostructured lipid carriers accumulate in atherosclerotic
    plaques of ApoE−/− mice», J. Vigne, C. Cabella, L. Dézsi,
    E. Rustique, A.-C. Couffin, R. Aid, N. Anizan, C. Chauvierre,
    D. Letourneur, D. Le Guludec, F. Rouzet, F. Hyafil, T. Mészáros,
    T. Fülöp, J. Szebeni, A. Cordaro, P. Oliva, V. Mourier, I. Texier,
    Nanomedicine: Nanotechnology, Biology, and Medicine 25,
    102157 DOI : 10.1016/j.nano. 2020.102157 (2020).
  • «Novel Nanosystems to Combat Atherosclerosis: Functional
    Effects on Endothelial and Monocytic Cells», I. Cicha,
    J. Matuszak, M. Juenet, C. Chauvierre, I. Texier, G. Almer,
    R. Prassl, J.M. Metselaar, L. Dézsi, R. Urbanics, J. Szebeni,
    C. Alexiou, H. Mangge, D. Letourneur, European Society of
    Cardiology Congress 2016 was published on Thursday 13th
    October in EMJ Cardiology 4.1, Rome, 27-31 August 2016.
  • «Biodistribution of Nanostructured Lipid Carriers in Mice
    Atherosclerotic Model», L. Devel, G. Almer, C. Cabella, F. Beau,
    M. Bernes, P. Oliva, F. Navarro, R. Prassl, H. Mangge, I. Texier,
    Molecules 24, 3499, doi:10.3390/molecules24193499
    (2019).




Investment:  € 12.8 m.

EC Contribution€ 9.8 m.



Website


Stakes

  • On the strength of its extensive previous experience in the nanomedicine field and, specifically, its proprietary know-how involving lipid-based nanoparticles, CEA-Leti completed 3 main technical Nano-Athero project tasks:
    • Development of 64Cu-B22280-F50, a new contrast agent for atherosclerotic plaque detection based on PET (Positon Emitting Tomography) imaging, which is one of the two sensitive imaging modalities for use in cardio-vascular treatment clinics
    • Development and implementation of mid-scale 64Cu-B22280-F50 production to prepare a clinical translation phase (i.e. a production process that is ready to use for clinical trials in a GMP environment)
    • Investigation of lipid-based nanoparticles as drug carriers for treating atherosclerotic plaques.

  • The nanometric size and natural affinity for lipid-rich areas enabled demonstration of CEA-Leti lipid-based nanoparticles (Lipidots™ technology) in efficiently and specifically targeting atherosclerotic plaques in rat animal models; their injection proved to be very safe. In comparison with currently investigated and reported clinical methods using recombined engineered lipoproteins, the CEA-Leti synthetic approach, based on natural or semi-synthetic products, ensures a better controlled, simpler and cheaper manufacturing process. Lipid-based nanoparticles are therefore of prime interest in further research into atherosclerosis diagnosis and could also be promising for long-term treatment of atherosclerotic plaque, when suitable, efficient drugs are identified.

OBJECTIVES

  • In acute coronary syndrome and stroke, atherosclerotic plaque disruption with superimposed thrombosis is the leading cause of mortality in the Western world. The Nano-Athero project brought together 15 European research groups involved in the nanomedicine field as technology developers and clinical groups involved in cross-disciplinary research in cardio-vascular diseases in a context of growing social and health costs. Nanosystems were developed for imaging and treatment of thrombus and plaque.
    • New nanoimaging agents allow non-invasive molecular imaging of key pathological processes in vulnerable plaques.
    • Nanosystems are used to delivery and increase drug efficiency for plaque and stroke treatments in humans.
    In the context of growing social and health costs of cardiovascular diseases, the Nano-Athero project’s main outcome was launching of a phase 1 clinical


IMPACT

  • In the context of growing social and health costs of cardiovascular diseases, the Nano-Athero project’s main outcome was launching of a phase 1 clinical trial on one nano-based contrast agent for atherosclerotic plaque
    detection. Two other nanosystems (including that of CEA-Leti) have been identified as promising for plaque imaging and therapy during preclinical experiments. These will now commence the long process involving the regulatory studies required for preparing clinical trials.